Luca Salvaderi
Luca Salvaderi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Blandino
Faculty of Medicine, Vita-Salute San Raffaele University, Milan, Italy
1 shared publication - Andrea Piccinini
Section of Legal Medicine and Insurance Medicine, Department of Biomedical Sciences for Health, University of Milan, Via Luigi Mangiagalli 37, 20133 Milan, Italy
1 shared publication - Andrea Termine
Data Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy
1 shared publication - Andrea Verzeletti
Institute of Legal Medicine, University of Brescia, Brescia, Italy
1 shared publication - Carla Bini
Section of Legal Medicine, Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy
1 shared publication - Carlo Fabrizio
Data Science Unit, Santa Lucia Foundation IRCCS, Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (4) , 70
Forensic Epigenetics for Casework: A Systematic Scoping Review of DNA Methylation-Centred Applications and Validation Evidence
Background/Objectives: Forensic epigenetics complements DNA profiling by informing donor age and trace origin, but technical promise does not establish casework validity. We mapped applications and validation evidence. Methods: Scopus, PubMed/MEDLINE and Web of Science were searched through 15 June 2026. Empirical reports were assigned a dominant application and an author-defined C1–C5 evidence category (not a readiness score). Results: Of 596 assessed full texts, 338 entered the evidence map (322 empirical studies and 16 contextual records). Among studies, 312/322 (96.9%) fell within C1–C3, 10 were C4 and none met the C5 definition of documented routine implementation in the indexed and retrievable corpus. C4 records advanced evaluation designs, which may reveal unsuccessful transfer or unresolved bias rather than acceptable casework performance. Age estimation (177 studies) and body-fluid/tissue identification (92) accounted for all C4 evidence. Of 272 identifiable methylation workflows, chemical conversion predominated; 23 studies were non-methylation, 26 reused methylation data without a new assay and one workflow remained unresolved. Conclusions: Published evidence is substantial but heterogeneous; internal performance cannot substitute for independent validation, inter-laboratory reproducibility, calibrated uncertainty, laboratory-specific procedures, controlled reporting and proportionate governance. Study-level counts do not quantify the proportion of distinct validated methods or establish absence of unindexed operational use.
- 2 November 2026
- Published by MDPI AG in Epigenomes
- Vol. 10 (4) , 70
Open AccessForensic Epigenetics for Casework: A Systematic Scoping Review of DNA Methylation-Centred Applications and Validation Evidence
Background/Objectives: Forensic epigenetics complements DNA profiling by informing donor age and trace origin, but technical promise does not establish casework validity. We mapped applications and validation evidence. Methods: Scopus, PubMed/MEDLINE and Web of Science were searched through 15 June 2026. Empirical reports were assigned a dominant application and an author-defined C1–C5 evidence category (not a readiness score). Results: Of 596 assessed full texts, 338 entered the evidence map (322 empirical studies and 16 contextual records). Among studies, 312/322 (96.9%) fell within C1–C3, 10 were C4 and none met the C5 definition of documented routine implementation in the indexed and retrievable corpus. C4 records advanced evaluation designs, which may reveal unsuccessful transfer or unresolved bias rather than acceptable casework performance. Age estimation (177 studies) and body-fluid/tissue identification (92) accounted for all C4 evidence. Of 272 identifiable methylation workflows, chemical conversion predominated; 23 studies were non-methylation, 26 reused methylation data without a new assay and one workflow remained unresolved. Conclusions: Published evidence is substantial but heterogeneous; internal performance cannot substitute for independent validation, inter-laboratory reproducibility, calibrated uncertainty, laboratory-specific procedures, controlled reporting and proportionate governance. Study-level counts do not quantify the proportion of distinct validated methods or establish absence of unindexed operational use.
- Open Access
NIPAT as Non-Invasive Prenatal Paternity Testing Using a Panel of 861 SNVs
In 1997, it was discovered that maternal plasma contains Cell-Free Fetal DNA (cffDNA). cffDNA has been investigated as a source of DNA for non-invasive prenatal testing for fetal pathologies, as well as for non-invasive paternity testing. While the advent of Next Generation Sequencing (NGS) led to the routine use of Non-Invasive Prenatal Screening (NIPT or NIPS), few data are available regarding the reliability and reproducibility of Non-Invasive Prenatal Paternity Testing (NIPPT or NIPAT). Here, we present a non-invasive prenatal paternity test (NIPAT) analyzing 861 Single Nucleotide Variants (SNV) from cffDNA through NGS technology. The test, validated on more than 900 meiosis samples, generated log(CPI)(Combined Paternity Index) values for designated fathers ranging from +34 to +85, whereas log(CPI) values calculated for unrelated individuals were below −150. This study suggests that NIPAT can be used with high accuracy in real cases.
Open AccessNIPAT as Non-Invasive Prenatal Paternity Testing Using a Panel of 861 SNVs
In 1997, it was discovered that maternal plasma contains Cell-Free Fetal DNA (cffDNA). cffDNA has been investigated as a source of DNA for non-invasive prenatal testing for fetal pathologies, as well as for non-invasive paternity testing. While the advent of Next Generation Sequencing (NGS) led to the routine use of Non-Invasive Prenatal Screening (NIPT or NIPS), few data are available regarding the reliability and reproducibility of Non-Invasive Prenatal Paternity Testing (NIPPT or NIPAT). Here, we present a non-invasive prenatal paternity test (NIPAT) analyzing 861 Single Nucleotide Variants (SNV) from cffDNA through NGS technology. The test, validated on more than 900 meiosis samples, generated log(CPI)(Combined Paternity Index) values for designated fathers ranging from +34 to +85, whereas log(CPI) values calculated for unrelated individuals were below −150. This study suggests that NIPAT can be used with high accuracy in real cases.